Sage Private Wealth Group LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 15.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,340 shares of the company's stock after selling 237 shares during the quarter. Sage Private Wealth Group LLC's holdings in Johnson & Johnson were worth $219,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Red Wave Investments LLC raised its holdings in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company's stock valued at $530,000 after buying an additional 59 shares during the period. Argus Investors Counsel Inc. raised its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company's stock valued at $1,941,000 after buying an additional 61 shares during the period. Alta Capital Management LLC raised its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company's stock valued at $2,808,000 after buying an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC increased its stake in Johnson & Johnson by 0.7% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company's stock worth $1,425,000 after purchasing an additional 62 shares during the period. Finally, Mason & Associates Inc increased its stake in Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company's stock worth $215,000 after purchasing an additional 62 shares during the period. 67.94% of the stock is owned by institutional investors.
Get Johnson & Johnson alerts:Wall Street Analysts Forecast Growth
A number of research firms have weighed in on JNJ. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research note on Friday, January 20th. Barclays began coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an "equal weight" rating and a $175.00 target price on the stock. Sanford C. Bernstein reduced their target price on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Raymond James cut their price target on Johnson & Johnson from $192.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 19th. Finally, Atlantic Securities raised their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research note on Wednesday, January 25th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $185.23.
Insider Transactions at Johnson & Johnson
In other news, CAO Robert J. Decker sold 16,928 shares of the firm's stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company's stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 198,365 shares of company stock worth $34,927,325 over the last three months. 0.35% of the stock is currently owned by insiders.Johnson & Johnson Price Performance
Shares of JNJ stock opened at $164.61 on Monday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The stock's 50-day moving average is $174.35 and its 200 day moving average is $170.54. The company has a market cap of $430.37 billion, a P/E ratio of 24.42, a PEG ratio of 2.83 and a beta of 0.54. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the company earned $2.13 earnings per share. Research analysts predict that Johnson & Johnson will post 10.51 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson's payout ratio is 67.06%.
Johnson & Johnson Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.